Investigating how certain mutations in protein kinase A contribute to rare tumors
Targeting Oncogenic PKA signaling mechanisms
This study is looking at how certain changes in a protein called PKA can cause rare tumors, and it's trying to find new ways to treat these cancers by understanding how these changes affect cell behavior.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11211314 on NIH RePORTER |
What this research studies
This research focuses on understanding the molecular mechanisms behind rare tumors, particularly those driven by mutations in protein kinase A (PKA). By examining how these mutations lead to abnormal cell signaling, the research aims to identify new therapeutic strategies. The approach involves profiling oncogenic PKA mutants and exploring their effects on protein translation in adrenal and hepatic tumors. This could lead to the development of targeted treatments that specifically address the unique characteristics of these rare cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rare endocrine or hepatic tumors associated with oncogenic PKA mutations.
Not a fit: Patients with common cancers or tumors not related to PKA signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective therapies for patients with rare tumors that currently lack approved treatments.
How similar studies have performed: Previous research has shown promise in targeting oncogenic mutations in protein kinases, suggesting that this approach could yield significant advancements in treating rare cancers.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Gordan, John D — University of California, San Francisco
- Study coordinator: Gordan, John D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.